Generation Bio Co.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yalonda Howze
- Full Time Employees
- 115
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 301 Binney Street Cambridge MA United States of America 02142
- IPO Date
- Jun 12, 2020
- CIK
- 0001733294
- Website
- generationbio.com
- Similar Companies
- Business
- Generation Bio Co. is a biotechnology firm dedicated to pioneering novel genetic medicines, strategically focusing its efforts on the development of siRNA therapeutics for T cell-driven autoimmune diseases. The company’s core approach leverages its proprietary cell-targeted lipid nanoparticle (ctLNP) delivery system, engineered to selectively transport gene-silencing molecules directly to T cells to address challenging targets in inflammatory conditions. This innovative platform represents a shift from earlier pursuits in broad rare and prevalent diseases of the liver and retina, now concentrating on the precise modulation of T cell activity. In recent developments, Generation Bio has demonstrated the ability of its ctLNP system to selectively target T cells in preclinical models, paving the way for potential investigational new drug applications anticipated in the second half of 2026. The company has also announced a strategic restructuring, including a significant workforce reduction, and is actively exploring strategic alternatives to maximize shareholder value amidst a challenging financial landscape. Formerly known as Torus Therapeutics, Inc., the company adopted the name Generation Bio Co. in November 2017. Established in 2016, Generation Bio Co. maintains its headquarters in Cambridge, Massachusetts.
Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide
Generation Bio Co. (NASDAQ:GBIO) Receives Average Recommendation of “Hold” from Brokerages
Brokerages Set Generation Bio Co. (NASDAQ:GBIO) PT at $9.25
Shareholder Alert: The Ademi Firm investigates whether Generation Bio Co. is obtaining a Fair Price for its Public Shareholders
GBIO Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Generation Bio Co. is Fair to Shareholders
XOMA Royalty Enters into Agreement to Acquire Generation Bio
Generation Bio Announces Third Quarter 2025 Financial Results
Comparing Generation Bio (NASDAQ:GBIO) & Nuvation Bio (NYSE:NUVB)
Generation Bio Announces CEO Transition
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results
Generation Bio Announces 1-for-10 Reverse Stock Split
Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Squarepoint Ops LLC Takes Position in Generation Bio Co. (NASDAQ:GBIO)
Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results
Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference
Generation Bio Co. (GBIO) Reports Q4 Loss, Tops Revenue Estimates
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results